Sorafenib for the treatment of renal cell carcinoma

Caren L. Hughes, Winston Tan, Marcus Ferrone

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To summarize the pharmacology, development, and clinical application of sorafenib, a specific tyrosine kinase and vascular growth factor inhibitor, for the treatment of renal cell carcinoma (RCC). Data Sources: Clinical literature, including both primary studies and review articles, was obtained by searching MEDLINE (1966-May 2006), using the search terms BAY 43-9006, sorafenib, renal cell carcinoma, and tyrosine kinase inhibitor. Additional information was supplied by the manufacturer, Bayer HealthCare Pharmaceuticals. Study Selection and Data Extraction: Review articles, abstracts, and clinical studies related to sorafenib were analyzed. An evaluation of the research exploring sorafenib as a potential therapy for RCC was conducted. Relevant information was then selected and is reviewed in this article. Data Synthesis: Knowledge of the cellular abnormalities that can cause solid tumors has led to the development of medications that block these pathways. Sorafenib is an oral tyrosine kinase inhibitor that both blocks the Raf kinase pathway and inhibits vascular growth factors. Phase I and II trials have demonstrated that sorafenib has activity against RCC. Dermatologic reactions (rash, desquamation), fatigue, and hypertension have been the most commonly seen treatment-related adverse events. Sorafenib received FDA approval in December 2005 for treatment of advanced RCC. Conclusions: Sorafenib is a novel oral tyrosine kinase inhibitor effective in the treatment of RCC.

Original languageEnglish (US)
Pages (from-to)281-288
Number of pages8
JournalJournal of Pharmacy Technology
Volume22
Issue number5
StatePublished - Sep 2006

Fingerprint

Renal Cell Carcinoma
Protein-Tyrosine Kinases
Intercellular Signaling Peptides and Proteins
raf Kinases
sorafenib
Growth Inhibitors
Clinical Pharmacology
Information Storage and Retrieval
Exanthema
MEDLINE
Fatigue
Hypertension
Delivery of Health Care
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Sorafenib for the treatment of renal cell carcinoma. / Hughes, Caren L.; Tan, Winston; Ferrone, Marcus.

In: Journal of Pharmacy Technology, Vol. 22, No. 5, 09.2006, p. 281-288.

Research output: Contribution to journalArticle

Hughes, CL, Tan, W & Ferrone, M 2006, 'Sorafenib for the treatment of renal cell carcinoma', Journal of Pharmacy Technology, vol. 22, no. 5, pp. 281-288.
Hughes, Caren L. ; Tan, Winston ; Ferrone, Marcus. / Sorafenib for the treatment of renal cell carcinoma. In: Journal of Pharmacy Technology. 2006 ; Vol. 22, No. 5. pp. 281-288.
@article{7a1edd7e3900450db83369d38c75d14f,
title = "Sorafenib for the treatment of renal cell carcinoma",
abstract = "Objective: To summarize the pharmacology, development, and clinical application of sorafenib, a specific tyrosine kinase and vascular growth factor inhibitor, for the treatment of renal cell carcinoma (RCC). Data Sources: Clinical literature, including both primary studies and review articles, was obtained by searching MEDLINE (1966-May 2006), using the search terms BAY 43-9006, sorafenib, renal cell carcinoma, and tyrosine kinase inhibitor. Additional information was supplied by the manufacturer, Bayer HealthCare Pharmaceuticals. Study Selection and Data Extraction: Review articles, abstracts, and clinical studies related to sorafenib were analyzed. An evaluation of the research exploring sorafenib as a potential therapy for RCC was conducted. Relevant information was then selected and is reviewed in this article. Data Synthesis: Knowledge of the cellular abnormalities that can cause solid tumors has led to the development of medications that block these pathways. Sorafenib is an oral tyrosine kinase inhibitor that both blocks the Raf kinase pathway and inhibits vascular growth factors. Phase I and II trials have demonstrated that sorafenib has activity against RCC. Dermatologic reactions (rash, desquamation), fatigue, and hypertension have been the most commonly seen treatment-related adverse events. Sorafenib received FDA approval in December 2005 for treatment of advanced RCC. Conclusions: Sorafenib is a novel oral tyrosine kinase inhibitor effective in the treatment of RCC.",
author = "Hughes, {Caren L.} and Winston Tan and Marcus Ferrone",
year = "2006",
month = "9",
language = "English (US)",
volume = "22",
pages = "281--288",
journal = "Journal of Pharmacy Technology",
issn = "8755-1225",
publisher = "Harvey Whitney Books Company",
number = "5",

}

TY - JOUR

T1 - Sorafenib for the treatment of renal cell carcinoma

AU - Hughes, Caren L.

AU - Tan, Winston

AU - Ferrone, Marcus

PY - 2006/9

Y1 - 2006/9

N2 - Objective: To summarize the pharmacology, development, and clinical application of sorafenib, a specific tyrosine kinase and vascular growth factor inhibitor, for the treatment of renal cell carcinoma (RCC). Data Sources: Clinical literature, including both primary studies and review articles, was obtained by searching MEDLINE (1966-May 2006), using the search terms BAY 43-9006, sorafenib, renal cell carcinoma, and tyrosine kinase inhibitor. Additional information was supplied by the manufacturer, Bayer HealthCare Pharmaceuticals. Study Selection and Data Extraction: Review articles, abstracts, and clinical studies related to sorafenib were analyzed. An evaluation of the research exploring sorafenib as a potential therapy for RCC was conducted. Relevant information was then selected and is reviewed in this article. Data Synthesis: Knowledge of the cellular abnormalities that can cause solid tumors has led to the development of medications that block these pathways. Sorafenib is an oral tyrosine kinase inhibitor that both blocks the Raf kinase pathway and inhibits vascular growth factors. Phase I and II trials have demonstrated that sorafenib has activity against RCC. Dermatologic reactions (rash, desquamation), fatigue, and hypertension have been the most commonly seen treatment-related adverse events. Sorafenib received FDA approval in December 2005 for treatment of advanced RCC. Conclusions: Sorafenib is a novel oral tyrosine kinase inhibitor effective in the treatment of RCC.

AB - Objective: To summarize the pharmacology, development, and clinical application of sorafenib, a specific tyrosine kinase and vascular growth factor inhibitor, for the treatment of renal cell carcinoma (RCC). Data Sources: Clinical literature, including both primary studies and review articles, was obtained by searching MEDLINE (1966-May 2006), using the search terms BAY 43-9006, sorafenib, renal cell carcinoma, and tyrosine kinase inhibitor. Additional information was supplied by the manufacturer, Bayer HealthCare Pharmaceuticals. Study Selection and Data Extraction: Review articles, abstracts, and clinical studies related to sorafenib were analyzed. An evaluation of the research exploring sorafenib as a potential therapy for RCC was conducted. Relevant information was then selected and is reviewed in this article. Data Synthesis: Knowledge of the cellular abnormalities that can cause solid tumors has led to the development of medications that block these pathways. Sorafenib is an oral tyrosine kinase inhibitor that both blocks the Raf kinase pathway and inhibits vascular growth factors. Phase I and II trials have demonstrated that sorafenib has activity against RCC. Dermatologic reactions (rash, desquamation), fatigue, and hypertension have been the most commonly seen treatment-related adverse events. Sorafenib received FDA approval in December 2005 for treatment of advanced RCC. Conclusions: Sorafenib is a novel oral tyrosine kinase inhibitor effective in the treatment of RCC.

UR - http://www.scopus.com/inward/record.url?scp=33750725795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750725795&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 281

EP - 288

JO - Journal of Pharmacy Technology

JF - Journal of Pharmacy Technology

SN - 8755-1225

IS - 5

ER -